

Biosimilars reimbursement update [1]

[Global Impact](#) [2]

Biosimilars reimbursement update

As of September 30, 2020, **PrZiextenzo**[®] [3] (pegfilgrastim) and **PrRiximyo**[®] [4] (rituximab for injection) are now eligible for reimbursement in Quebec through the **RAMQ's Public Prescription Drug Insurance Plan** [5].

In addition, both biosimilars are on the list of medicines and establishments for use in Canadian hospitals.

As of October 7, 2020, **PrRiximyo**[®] [4] is also eligible for reimbursement in Nova Scotia through the **Nova Scotia Pharmacare**. [5]

For more information on Sandoz biosimilars click **here** [6] and to get evidence-based information on biosimilars in Canada visit **The Biosimilars Generation web site** [7].



Source URL: <https://www.sandoz.ca/en/stories/global-impact/biosimilars-reimbursement-update>

Links

[1] <https://www.sandoz.ca/en/stories/global-impact/biosimilars-reimbursement-update>

[2] <https://www.sandoz.ca/en/stories/global-impact>

[3] <https://www.sandoz.ca/en/products/patients/biosimilars/ziextenzo>

[4] <https://www.sandoz.ca/en/products/patients/biosimilars/Riximyo>

[5] <https://urldefense.proofpoint.com/v2/url?u=https->

3A__www.ramq.gouv.qc.ca_SiteCollectionDocuments_professionnels_medicaments_liste-2Dmed-

5F2020-2D09_Liste-5Fmedicaments-5Ffr-5F2020-

2D09.pdf&d=DwMFAw&c=ZbgFmJjg4pdtrnL2HUJUDw&r=XmszeXrgiCu74-

PV2ygRfl1Di8TxvfZ_UGnHU1PCHsc&m=_biYa8M_cTjah7Zs7RHrl6ln9qRo7mD8fa6gS68HIQk&s=4eMwf

b2MYUyBP8hnSXpU7af_OzU&e=

[6] <https://www.sandoz.ca/en/biosimilars>

[7] <https://C:/Users/COURTLA6/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/HKR6LYRM/biosimilars>